Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library

Hou, Lidan; Zhu, Da‐Yuan; Yu, Liang; Tian, Xingui; Li, Lei; Wang, Ping; Zhu, Liming; Weng, Xiaoling; Wang, Yingying; Li, Yue; Wu, Tianqi; Wang, Jianhua; Meng, Xiangjun

doi:10.1038/bjc.2017.366

Cited by 19 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the tumour as abundantly as other candidate peptides and hence were not studied further. DWSSWVYRDPQT peptide identified in this study reportedly targets colon cancer cells in vitro with in silico analysis suggesting the peptide targets glypican-3 (a heparin sulphate proteoglycan (HSPG)) [47]. We checked all peptides identified in this study with SAROTUP (Scanner and Reporter of Target Un-related peptides).…”

Section: Discussionmentioning

confidence: 99%

“…We checked all peptides identified in this study with SAROTUP (Scanner and Reporter of Target Un-related peptides). The DWSSWVYRDPQT peptide is considered a potentially false-positive peptide where the sequence WXXW binds plastic with no actual affinity towards the target but rather the (plastic surface) solid phase [48], although data from others [47] would suggest otherwise.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapies (OV) based on human adenoviral (HAdV) vectors hold significant promise for the treatment of advanced ovarian cancers where local, intraperitoneal delivery to tumour metastases is feasible, bypassing many complexities associated with intravascular delivery. The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FRα) is highly expressed on ovarian cancer cells, providing a compelling target for tumour selective delivery of virotherapies. Here, we identify high-affinity FRα-binding oligopeptides for genetic incorporation into HAdV-C5 vectors. Biopanning identified a 12-mer linear peptide, DWSSWVYRDPQT, and two 7-mer cysteine-constrained peptides, CIGNSNTLC and CTVRTSAEC that bound FRα in the context of the phage particle. Synthesised lead peptide, CTVRTSAEC, bound specifically to FRα and could be competitively inhibited with folic acid. To assess the capacity of the elucidated FRα-binding oligopeptides to target OV to FRα, we genetically incorporated the peptides into the HAdV-C5 fiber-knob HI loop including in vectors genetically ablated for hCAR interactions. Unfortunately, the recombinant vectors failed to efficiently target transduction via FRα due to defective intracellular trafficking following entry via FRα, indicating that whilst the peptides identified may have potential for applications for targeted drug delivery, they require additional refinement for targeted virotherapy applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Tumor-targeting peptides for diagnosis and therapy, 2021, 5 (1) cause of cancer death around the world [28] . The peptide, CBP-DWS (DWSSWVYRDPQT), was confirmed showing high affinity for COLO320HSR (human colon cell line) rather than NCM460 (the normal human intestinal epithelial cell line) by phage display technology [29] .…”

Section: Specific Peptides Binding To Tum-or Cellsmentioning

confidence: 99%

Screening of tumor-targeting peptides for diagnosis and therapy through phage display technology

Song¹,

Zhang²,

Zhu³

et al. 2021

Blood and Genomics

View full text Add to dashboard Cite

Phage display technology was introduced by G. Smith in 1985, which is highly effective in the selection of affinity peptides from a library containing billions of display peptides. The obtained peptides show potential efficacy in the development of further clinical applications, especially in tumor treatment. In this review, the basic principles, limits, developments of phage display technology and peptide libraries are introduced. Following that, the amino acid sequence of tumor target peptides for hematological and other systems are discussed. Finally, the application of target peptides in the design of imaging probes and the development of target peptide drugs for diagnosis and therapy are noted.

show abstract

“…A Cy5.5-labeled 12mer peptide, SRRPASFRTARE specifically binding to Barrett’s esophagus was selected, characterized, and reported as a candidate to be developed as a probe for the detection of early esophagus cancer and pre-malignant mucosa (Zhou et al 2017 ). By now, fluorescent labeled peptide probes have been successfully used in imaging diagnosis of multiple tumors (Haque et al 2019 ; Hou et al 2018 ; Jing et al 2018 ; Lee et al 2016 ; Li et al 2017 ; Scodeller et al 2017 ; Xing et al 2018 ; Zhang et al 2015 ).…”

Section: Potential Applications Of Targeting Peptidesmentioning

confidence: 99%

Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy

Xü

et al. 2020

Int J Pept Res Ther

View full text Add to dashboard Cite

Phage display is an effective and powerful technique that provides a route to discovery unique peptides targeting to tumor cells. Specifically binding peptides are considered as the valuable target directing molecule fragments with potential efficiency to improve the current tumor clinic, and offer new approaches for tumor prevention, diagnosis and treatment. We focus on the recent advances in the isolation of tumor-targeting peptides by biopanning methods, with particular emphasis on molecular imaging, and pharmaceutical targeting therapy.

show abstract

Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library

Abstract: These studies suggest that the selected peptide CBP-DWS may be a candidate to serve as a novel probe for colon cancer imaging.

Cited by 19 publications

References 25 publications

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications

Screening of tumor-targeting peptides for diagnosis and therapy through phage display technology

Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy

Contact Info

Product

Resources

About